Claims for Patent: 8,530,425

Summary for Patent: 8,530,425

Title:	Targeted delivery of botulinum toxin to the sphenopalatine ganglion
Abstract:	Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.
Inventor(s):	Blumenfeld; Andrew M. (Del Mar, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/158,894
Patent Claims:	1. A method for reduction of pain associated with a headache in a mammal in need thereof, comprising the step of administering a therapeutically effective amount of a botulinum toxin selected from the group consisting of botulinum toxin type A, B, C.sub.1, D, E and F along the trajectory of an extracranial artery and to a sphenopalatine ganglion, wherein the extracranial artery is selected from the group consisting of a temporal artery and an occipital artery, thereby effecting reduction of headache pain in the mammal in need thereof. 2. The method of claim 1, wherein the botulinum toxin is administered by injection. 3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type B. 4. The method of claim 1, wherein the headache is selected from the group consisting of migraine, trigeminal autonomic cephalgia and headache caused by a vascular condition. 5. The method of claim 1, further comprising the step of locating the extracranial artery. 6. The method of claim 5, wherein the step of locating the extracranial artery utilizes palpation. 7. The method of claim 1, wherein administration to the sphenopalatine is performed bilaterally. 8. The method of claim 1, wherein administration of botulinum toxin is to a plurality of locations adjacent the sphenopalatine ganglion. 9. A method for reduction of a pain associated with a headache in a mammal in need thereof, the method comprising the steps of; determining the projection of an extracranial artery wherein the extracranial artery is selected from the group consisting of a temporal artery and an occipital artery; infiltrating an area around the extracranial artery with a therapeutically effective amount of a botulinum toxin selected from the group consisting botulinum toxin type A, B, C.sub.1, D, E, F and G; administering botulinum toxin to a sphenopalatine ganglion, thereby reducing the pain associated with the headache. 10. The method of claim 9, wherein the determining step utilizes palpation to determine the projection of the extracranial artery. 11. The method of claim 9, wherein the step of infiltrating the area around the extracranial artery utilizes injection or topical administration of botulinum toxin. 12. The method of claim 9, wherein the step of administering botulinum toxin to the sphenopalatine ganglion utilizes injection or topical administration of botulinum toxin. 13. The method of claim 9 wherein the infiltrating and administering steps are performed unilaterally or bilaterally. 14. The method of claim 9, wherein the headache is selected from the group consisting of migraine, trigeminal autonomic cephalgia and headache caused by a vascular condition. 15. A method of reducing pain, wherein the pain is associated with a headache, in a mammal in need thereof, comprising: a first administering step wherein a therapeutically effective amount of a botulinum toxin selected from the group consisting of botulinum toxin type A, B, C.sub.1, D, E, F and G is administered along the trajectory of an extracranial artery wherein the extracranial artery is selected from the group consisting of a temporal artery and an occipital artery; and a second administering step, wherein a therapeutically effective amount of botulinum toxin is administered to a sphenopalatine ganglion, wherein the second administration step is provided when prior treatment targeted to the extracranial artery do not provide sufficient results, thereby reducing the pain associated with the headache. 16. The method of claim 15, wherein the second administration step of botulinum toxin to the sphenopalatine ganglion is via an injection site. 17. The method of claim 15, wherein the injection site is midway between the tragus of the ear and outer cantus of the eye. 18. The method of claim 15, wherein the botulinum toxin is botulinum toxin type B.

Details for Patent 8,530,425

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2025-02-01